Overview

Peptide Receptor Radionuclide Therapy With 177Lu-Dotatate Associated With Metronomic Capecitabine In Patients Affected By Aggressive Gastro-Etero-Pancreatic Neuroendocrine Tumors

Status:
Active, not recruiting

Trial end date:
2021-06-01

Target enrollment:

Participant gender:

Summary

The aim of this phase I-II study is to evaluate the efficacy and toxicity of PRRT with 177Lu-DOTATATE (Lu-PRRT) associated to metronomic chemotherapy with Capecitabine in patients affected by aggressive FDG-positive gastro-entero-pancreatic NET. Moreover to analyze the effects of the capecitabine metronomic schedule on the level of circulating angiogenetic factors.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori

Collaborator:

Istituto Europeo di Oncologia IEO MILANO

Treatments:

Capecitabine
Lutetium Lu 177 dotatate
Octreotide